

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

February 1, 2022

Paul R. Edick Chairman and Chief Executive Officer Xeris Biopharma Holdings, Inc. 180 N. LaSalle Street, Suite 1600 Chicago, Illinois 60601

> Re: Xeris Biopharma Holdings, Inc. Registration Statement on Form S-3 Filed January 28, 2022 File No. 333-262404

Dear Mr. Edick:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Michael Davis at 202-551-4385 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Joseph C. Theis, Jr., Esq.